Drug
Etentamig clinical trials
Also written TNB-383B and ABBV-383.
- studies test it
- 13
- open now
- 9
- in phase 3
- 4
- first study started
- 2019
Keep track of what changes. Save the etentamig studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Name
Studies by the year they started
13 studies that test it; most in 2026 (5)
| Year | Studies |
|---|---|
| 2019 | 1 |
| 2022 | 1 |
| 2023 | 1 |
| 2024 | 3 |
| 2025 | 2 |
| 2026 | 5 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 9
- Phase 2
- 6
- Phase 3
- 4
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 11 · Other 2
AbbVie (11) · Universitätsklinikum Hamburg-Eppendorf (1) · Mayo Clinic (1)
Often tested with
Tested in the same studies.
Dexamethasone (4) · Pomalidomide (3) · Lenalidomide (3) · Carfilzomib (2) · Bortezomib (2) · Elotuzumab (1) · Selinexor (1) · Isatuximab (1)
Studies
Open first, then newest update. How each study uses etentamig is read from its arms, and is right about nine times in ten.
Testing it · 13
- A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving T Cell Engaging Bi/Tri-specific Antibodies Intravenously (IV)/Subcutaneously (SC) Alone or in CombinationsRecruitingPhase 1/2AbbVieNCT06892522Written as Etentamig
- A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for TransplantRecruitingPhase 2/3AbbVieNCT07095452Written as Etentamig
- ABBV-383 for the Treatment of Relapsed Refractory Waldenström MacroglobulinemiaRecruitingPhase 1/2Mayo ClinicNCT07420959Written as Etentamig
- Study to Evaluate Change in Disease Activity and Adverse Events of Subcutaneous Etentamig Compared With Daratumumab Plus Cyclophosphamide Plus Bortezomib Plus Dexamethasone (Dara-CyBorD) in Adults With Amyloid Light Chain (AL) AmyloidosisNot yet recruitingPhase 3AbbVieNCT07793422Written as Etentamig
- A Study to Evaluate Adverse Events and Change in Disease Activity With Injected Etentamig Plus Oral Pomalidomide Versus Standard Therapies in Adults With Relapsed or Refractory Multiple MyelomaNot yet recruitingPhase 3AbbVieNCT07728188Written as Etentamig
- A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple MyelomaRecruitingPhase 1AbbVieNCT05650632Written as Etentamig (ABBV-383)
- Etenta-Isa-VRd in Newly Diagnosed High-Risk Multiple MyelomaNot yet recruitingPhase 1/2Universitätsklinikum Hamburg-EppendorfNCT07600151Written as Etentamig
- A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Immunoglobulin Light Chain (AL) Amyloidosis Receiving Etentamig (ABBV-383) as an Intravenous (IV) InfusionRecruitingPhase 1/2AbbVieNCT06158854Written as ABBV-383 (Etentamig)
- Study of Intravenously (IV) Infused Etentamig in Combination With an Oral Cereblon E3 Ligase Modulatory Drug (CELMoD) Agent Assessing Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple MyelomaRecruitingPhase 1AbbVieNCT06896916Written as Etentamig
- Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple MyelomaActive, not recruitingPhase 3AbbVieNCT06158841Written as Etentamig
- Study of ABBV-383 Assessing Adverse Events and Clinical Activity With Subcutaneous (SC) Injection in Adult Participants With Relapsed or Refractory Multiple MyelomaActive, not recruitingPhase 1AbbVieNCT06223516Written as Subcutaneous (SC) Etentamig
- A Study of TNB-383B in Participants With Relapsed or Refractory Multiple MyelomaActive, not recruitingPhase 1/2AbbVieNCT03933735Written as TNB-383B
- A Study to Assess Adverse Events and Change in Disease State of Intravenously (IV) Infused Etentamig (ABBV-383) of Adult Participants With Relapsed or Refractory Multiple Myeloma in JapanActive, not recruitingPhase 1AbbVieNCT05286229Written as Etentamig
Given in every arm · 2 — etentamig is usual care beside what is tested
- A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)RecruitingPhase 1/2AbbVieNCT06953960Written as Etentamig
- A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused Etentamig (ABBV-383) in Combination With Anti-Cancer Regimens for the Treatment of Adult Participants With Relapsed/Refractory Multiple MyelomaActive, not recruitingPhase 1AbbVieNCT05259839Written as Etentamig
Codes
What other systems call etentamig · ClinicalTrials.gg INT016241
- UNII (FDA) CO86AOP337ETENTAMIGOne source FDA
- NCI Thesaurus C164668EtentamigOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | CO86AOP337 | ETENTAMIG | One source FDA |
| NCI Thesaurus | C164668 | Etentamig | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.